IP Library Granted Patent US 8,343,515
Granted Patent B2
US 8,343,515 · App. 12/590,996 · Granted Jan 1, 2013

Perfluorocarbon gel formulations

Assignee: Oxygen Biotherapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,343,515
App. No.
12/590,996
Granted
Jan 1, 2013
Kind
B2
Abstract

A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.

Claims (27)

1. A perfluorocarbon gel composition comprising 84-90 wt % perfluorocarbon and 8-11 wt % water and 2-4 wt % surfactants relative to the total weight of the gel, wherein the perfluorocarbon is perfluoro(tert-butylcyclohexane).

2. The perfluorocarbon gel composition of claim 1 , wherein the surfactants include polyoxyethylene-polyoxypropylene block copolymers.

3. The perfluorocarbon gel composition of claim 2 , wherein the polyoxyethylene-polyoxypropylene block copolymers include Poloxamer 105 and/or Poloxamer 188.

4. The perfluorocarbon gel composition of claim 1 , wherein the composition further comprises 0.01-6 wt % Vitamin E.

5. The perfluorocarbon gel composition of claim 4 , wherein the composition comprises 0.03 wt % Vitamin E.

6. The perfluorocarbon gel composition of claim 1 , wherein the composition further comprises 0.02-3.20 wt % preservatives.

7. The perfluorocarbon gel composition of claim 1 , wherein the composition comprises 90 wt % perfluorocarbon, 8 wt % water, and 2 wt % surfactants.

8. The perfluorocarbon gel composition of claim 1 , wherein the composition comprises 86.86 wt % perfluorocarbon, 10.42 wt % water, 2.69 wt % surfactants and 0.03 wt % Vitamin E.

9. The perfluorocarbon gel composition of claim 8 , wherein the composition comprises 86.86 wt % perfluoro(tert-butylcyclohexane), 10.42 wt % water, 2.43 wt % Poloxamer 105, 0.26 Wt % Poloxamer 188 and 0.03 wt % Vitamin E.

10. The perfluorocarbon gel composition of claim 1 , characterized by that it continuously delivers oxygen to a tissue at a rate of 0.2 cc/hour −20.0 cc/hour for up to 24 hours.

11. The perfluorocarbon gel composition of claim 10 , wherein the composition continuously delivers oxygen to the tissue at a rate of 2.0 cc/hour for 24 hours.

12. The perfluorocarbon gel composition of claim 1 , further comprising urea hydrogen peroxide.

13. A process of manufacturing the perfluorocarbon gel composition of claim 1 comprising the steps:

a) mixing water and surfactants—as an aqueous phase in a vessel;

b) homogenizing the mixture;

c) adding perfluorocarbon to the mixture over time during high speed homogenization; and

d) obtaining the gel.

14. The process of claim 13 , wherein in step a) the aqueous phase include distilled water, as said water, surfactants, and further optionally, preservatives.

15. The process of claim 13 , wherein in step a) the vessel is a glass, polyethylene, PET, or stainless steel vessel.

16. The process of claim 13 , wherein in step b) the homogenizer is a rotor stator homogenizer.

17. The process of claim 13 , wherein in step b) the mixture is homogenized for 4-6 minutes.

18. The process of claim 17 , wherein step b) the mixture is homogenized for 5 minutes.

19. The process of claim 13 , wherein in step b) the mixture is homogenized at 10,000-35,000 RPM.

20. The process of claim 13 , wherein in step c) the perfluorocarbon is added in aliquots or continuously over 10-30 minutes.

21. The perfluorocarbon gel composition of claim 1 , comprising 84-90 wt % perfluorocarbon, 9-11 wt % water, and 2-4 wt % surfactants, and 0.02-3.20 wt % preservatives relative to the total weight of the gel.

22. The perfluorocarbon gel composition of claim 21 , wherein the surfactants are polyoxyethylene-polyoxypropylene block copolymers.

23. The perfluorocarbon gel composition of claim 22 , wherein the polyoxyethylene-polyoxypropylene block copolymers include Poloxamer 105.

Assignments (2)
CHANGE OF NAME Recorded Oct 30, 2014
From: OXYGEN BIOTHERAPEUTICS, INC.
To: TENAX THERAPEUTICS, INC
Reel/Frame 034112/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2010
From: HUVARD, GARY; KIRAL, RICHARD; QUITARO, MAXINE; THOMPSON, DEBORAH P.; GROSSMAN, AHARON; CLAUSON, GARY; SANDHU, GURBHAGAT
To: OXYGEN BIOTHERAPEUTICS, INC.
Reel/Frame 023948/0708 →
Continuity (5)
Continuation In Part 12589202 · Oct 19, 2009
Provisional Application 61200254 · Nov 25, 2008
Provisional Application 61204785 · Jan 9, 2009
Provisional Application 61205499 · Jan 21, 2009
Related Publication 20100144861A1 · Jun 10, 2010